Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium triple live bacteria
- Development stage
- Unknown
- Lead developer
- China Resources Group
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium triple live bacteria tablets is a probiotic drug formulation containing three live bacterial strains: *Bifidobacterium longum*, *Lactobacillus bulgaricus*, and *Streptococcus thermophilus*. It is primarily used to regulate intestinal flora and treat dysbiosis-related conditions such as diarrhea and constipation. In recent clinical research, it is being evaluated as an adjunctive therapy for cardiovascular and neurological conditions, including unstable angina pectoris and acute ischemic stroke. The drug's mechanism involves modulating the gut microbiota to reduce the production of pro-atherogenic metabolites like trimethylamine N-oxide (TMAO) via the gut-liver-heart axis. It is manufactured by companies such as Jincheng Haise Pharmaceutical in China.
- Other names
- Bifid Triple Viable PreparationBifid Triple Viable TabletBifidobacterium Triple Live Bacteria Tablets
02
Targets
Trimethylamine-producing gut microbial metabolic pathways
Beyond the preview
Go deeper on bifidobacterium triple live bacteria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium triple live bacteria.